We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
United Therapeutics PAH Drug's Exclusivity Period Extended
Read MoreHide Full Article
United Therapeutics Corporation (UTHR - Free Report) reported that the FDA has granted six months pediatric exclusivity to its pulmonary arterial hypertension (PAH) drug, Adcirca (tadalafil). This will delay generic competition for the drug for an additional six months.
The pediatric exclusivity has pushed back patent expiry of the oral PDE-5 inhibitor to May 2018. The patent was otherwise set to expire this month. This means a generic version of the drug cannot be approved until then.
Shares of United Therapeutics were up 2.6% on Monday, in response to the positive development. However, a look at United Therapeutics’ share price movement shows that the stock has underperformed the industry this year so far. United Therapeutics stock has declined 12% during this period, while the industry rose 2%.
We remind investors that United Therapeutics bought exclusive rights to commercialize Adcirca for the treatment of PAH in the United States from Eli Lilly (LLY - Free Report) in November 2008. Tadalafil is also sold by Lilly as Cialis for erectile dysfunction.
The additional exclusivity for Adcirca was based on some study data submitted by Lilly to the FDA.
Separately, United Therapeutics will be required to pay higher royalties on sales of Adcirca, effective from next month, per a previously announced amendment to the licensing agreement. The royalty rate on Adcirca sales is up from 5% to 10%. United Therapeutics also has to make milestone payments of $325,000 for each $1,000,000 in net product sales.
Adcirca generated sales of $300.4 million in the nine months of 2017, up 15.8% year over year.
Meanwhile, the company has three more PAH products in its portfolio – Remodulin, Tyvaso and Orenitram. With these products, United Therapeutics has a varied range of therapies targeting the PAH market.
Lately, growth of Orenitram, Tyvaso and Remodulin has slowed down due to competition, mainly from Actelion’s new drug, Uptravi (selexipag). Actelion is now part of Johnson & Jonson (JNJ - Free Report) . Also some patients are staying longer on front-line oral AMBITION combination therapy (Adcirca + Gilead’s (GILD - Free Report) Letairis) and delaying the transition to inhaled/injectable therapies like Tyvaso/Remodulin, thereby hurting their demand.
Meanwhile, Remodulin, which accounts for more than 35% of United Therapeutics’ total sales, could start facing generic competition after June 2018.
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Image: Bigstock
United Therapeutics PAH Drug's Exclusivity Period Extended
United Therapeutics Corporation (UTHR - Free Report) reported that the FDA has granted six months pediatric exclusivity to its pulmonary arterial hypertension (PAH) drug, Adcirca (tadalafil). This will delay generic competition for the drug for an additional six months.
The pediatric exclusivity has pushed back patent expiry of the oral PDE-5 inhibitor to May 2018. The patent was otherwise set to expire this month. This means a generic version of the drug cannot be approved until then.
Shares of United Therapeutics were up 2.6% on Monday, in response to the positive development. However, a look at United Therapeutics’ share price movement shows that the stock has underperformed the industry this year so far. United Therapeutics stock has declined 12% during this period, while the industry rose 2%.
We remind investors that United Therapeutics bought exclusive rights to commercialize Adcirca for the treatment of PAH in the United States from Eli Lilly (LLY - Free Report) in November 2008. Tadalafil is also sold by Lilly as Cialis for erectile dysfunction.
The additional exclusivity for Adcirca was based on some study data submitted by Lilly to the FDA.
Separately, United Therapeutics will be required to pay higher royalties on sales of Adcirca, effective from next month, per a previously announced amendment to the licensing agreement. The royalty rate on Adcirca sales is up from 5% to 10%. United Therapeutics also has to make milestone payments of $325,000 for each $1,000,000 in net product sales.
Adcirca generated sales of $300.4 million in the nine months of 2017, up 15.8% year over year.
Meanwhile, the company has three more PAH products in its portfolio – Remodulin, Tyvaso and Orenitram. With these products, United Therapeutics has a varied range of therapies targeting the PAH market.
Lately, growth of Orenitram, Tyvaso and Remodulin has slowed down due to competition, mainly from Actelion’s new drug, Uptravi (selexipag). Actelion is now part of Johnson & Jonson (JNJ - Free Report) . Also some patients are staying longer on front-line oral AMBITION combination therapy (Adcirca + Gilead’s (GILD - Free Report) Letairis) and delaying the transition to inhaled/injectable therapies like Tyvaso/Remodulin, thereby hurting their demand.
Meanwhile, Remodulin, which accounts for more than 35% of United Therapeutics’ total sales, could start facing generic competition after June 2018.
United Therapeutics carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>